WHO Pharmaceuticals Newsletter 2000, No. 01
(2000; 18 pages)
Table of Contents
View the documentEditorial
Close this folderRegulatory matters
View the documentAnorectic agents - suspension of marketing authorizations
View the documentCisapride - New warnings concerning cardiac effects and voluntary withdrawal
View the documentCytarabine - Batch recalled: adverse reaction
View the documentDidanosine in combination - Warning concerning deaths due to pancreatitis
View the documentHypericum perforatum (St John's Wort) - Recommendations for use
View the documentInsulin preparations - Withdrawal of 40 IU/mL formulations
View the documentInsulin (human) cartridges - Warning: risk of leakage
View the documentMethotrexate - Revised data sheet: adverse reactions
View the documentNevirapine - Severe and life-threatening cutaneous and hepatic reactions
View the documentNimesulide (paediatric) - Application for an export licence refused
View the documentPemoline (Cylert®) - Withdrawn from the market
View the documentReteplase - Incompatibility with heparin and precipitation following reconstitution
View the documentTiratricol - Warning: promoted for inappropriate use
View the documentTrade name duplication - Risk of errors
View the documentAnnouncement: ICH 5, San Diego, California, USA, November 2000
Open this folder and view contentsSafety of medicines
View the documentFeature: Immunization safety: a global priority
View the documentFiller: WHO/UNICEF vaccine quality surveys
View the documentSafety of vaccines: Registration of vaccines
 

Hypericum perforatum (St John's Wort) - Recommendations for use

France. Following the recent publication of several papers describing significant interactions between Hypericum perforatum and digoxin, theophylline, indinavir, ciclosporin, certain oral anticoagulants, antidepressants and oral contraceptives, the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSPS) has made the following recommendations:

Patients under medicinal treatment who are not taking Hypericum perforatum.

• Patients being treated with antiretroviral agents, and particularly indinavir (Crixivan), for HIV infection should not take Hypericum perforatum in view of the risk of a diminution in the efficacy of the treatment.

• Patients being treated with antidepressants should not take Hypericum perforatum concomitantly because of the risk of adverse reactions (restlessness, nausea, gastric disturbance).

• Women taking oral contraceptives should not take Hypericum perforatum concomitantly because of the risk of a diminution in the contraceptive effect.

• In general, Hypericum perforatum should not be taken concomitantly with any other medicinal treatment in view of the risk of a drug interaction which could result in a reduction in the efficacy of the medicines.

Patients under medicinal treatment who are taking Hypericum perforatum.

• Patients who are receiving a medicinal treatment and who are also taking Hypericum perforatum must not stop taking Hypericum perforatum abruptly without medical advice.

Although Hypericum perforatum has been promoted as a treatment for mood disorders and is available as a food supplement, it has not been approved as a medicine in France.

[See also Information Exchange Alert No. 96, 3 March 2000]

Reference: Communiqué from the Agence Française de Sécurité Sanitaire des Produits de Santé, 1 March 2000.

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: October 29, 2018